Literature DB >> 23972477

Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors.

Yevgeny Brudno1, Alessandra B Ennett-Shepard, Ruth R Chen, Michael Aizenberg, David J Mooney.   

Abstract

Therapeutic stimulation of angiogenesis to re-establish blood flow in ischemic tissues offers great promise as a treatment for patients suffering from cardiovascular disease or trauma. Since angiogenesis is a complex, multi-step process, different signals may need to be delivered at appropriate times in order to promote a robust and mature vasculature. The effects of temporally regulated presentation of pro-angiogenic and pro-maturation factors were investigated in vitro and in vivo in this study. Pro-angiogenic factors vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2) cooperatively promoted endothelial sprouting and pericyte detachment in a three-dimensional in vitro EC-pericyte co-culture model. Pro-maturation factors platelet-derived growth factor B (PDGF) and angiopoietin 1 (Ang1) inhibited the early stages of VEGF- and Ang2-mediated angiogenesis if present simultaneously with VEGF and Ang2, but promoted these behaviors if added subsequently to the pro-angiogenesis factors. VEGF and Ang2 were also found to additively enhance microvessel density in a subcutaneous model of blood vessel formation, while simultaneously administered PDGF/Ang1 inhibited microvessel formation. However, a temporally controlled scaffold that released PDGF and Ang1 at a delay relative to VEGF/Ang2 promoted both vessel maturation and vascular remodeling without inhibiting sprouting angiogenesis. Our results demonstrate the importance of temporal control over signaling in promoting vascular growth, vessel maturation and vascular remodeling. Delivering multiple growth factors in combination and sequence could aid in creating tissue engineered constructs and therapies aimed at promoting healing after acute wounds and in chronic conditions such as diabetic ulcers and peripheral artery disease.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Controlled drug release; Drug delivery; Endothelial cell; Growth factors; Smooth muscle cell

Mesh:

Substances:

Year:  2013        PMID: 23972477      PMCID: PMC3811005          DOI: 10.1016/j.biomaterials.2013.08.007

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  65 in total

1.  Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones.

Authors:  William W Yuen; Nan R Du; Chun H Chan; Eduardo A Silva; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery.

Authors:  Muge Yemisci; Yasemin Gursoy-Ozdemir; Atay Vural; Alp Can; Kamil Topalkara; Turgay Dalkara
Journal:  Nat Med       Date:  2009-08-30       Impact factor: 53.440

3.  Modulating Notch signaling to enhance neovascularization and reperfusion in diabetic mice.

Authors:  Lan Cao; Praveen R Arany; Jaeyun Kim; José Rivera-Feliciano; Yuan-Shuo Wang; Zhiheng He; Christian Rask-Madsen; George L King; David J Mooney
Journal:  Biomaterials       Date:  2010-08-25       Impact factor: 12.479

4.  Effects of VEGF temporal and spatial presentation on angiogenesis.

Authors:  Eduardo A Silva; David J Mooney
Journal:  Biomaterials       Date:  2009-11-10       Impact factor: 12.479

5.  Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors.

Authors:  Cristina Borselli; Hannah Storrie; Frank Benesch-Lee; Dmitry Shvartsman; Christine Cezar; Jeff W Lichtman; Herman H Vandenburgh; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

Review 6.  Therapeutic angiogenesis in the management of critical limb ischemia: current concepts and review.

Authors:  Steve Attanasio; Jeffrey Snell
Journal:  Cardiol Rev       Date:  2009 May-Jun       Impact factor: 2.644

7.  Cyclic tensile strain triggers a sequence of autocrine and paracrine signaling to regulate angiogenic sprouting in human vascular cells.

Authors:  Yu Ching Yung; Jeiwook Chae; Markus J Buehler; Craig P Hunter; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

Review 8.  The pericyte: cellular regulator of microvascular blood flow.

Authors:  Matthew E Kutcher; Ira M Herman
Journal:  Microvasc Res       Date:  2009-02-07       Impact factor: 3.514

9.  Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling.

Authors:  Lan Cao; Praveen R Arany; Yuan-Shuo Wang; David J Mooney
Journal:  Biomaterials       Date:  2009-05-29       Impact factor: 12.479

10.  Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis.

Authors:  Nan Song; Yujie Huang; Hubing Shi; Shaopeng Yuan; Yanping Ding; Xiaomin Song; Yan Fu; Yongzhang Luo
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

View more
  68 in total

Review 1.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

2.  Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction.

Authors:  Hassan K Awada; Noah R Johnson; Yadong Wang
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

3.  Hyperactive FOXO1 results in lack of tip stalk identity and deficient microvascular regeneration during kidney injury.

Authors:  Lan T H Dang; Takahide Aburatani; Graham A Marsh; Bryce G Johnson; Stella Alimperti; Christine J Yoon; Angela Huang; Suzanne Szak; Naoki Nakagawa; Ivan Gomez; Shuyu Ren; Sarah K Read; Chris Sparages; Alfred C Aplin; Roberto F Nicosia; Chris Chen; Giovanni Ligresti; Jeremy S Duffield
Journal:  Biomaterials       Date:  2017-07-07       Impact factor: 12.479

4.  A Prospective, Nonrandomized, no Placebo-Controlled, Phase I/II Clinical Trial Assessing the Safety and Efficacy of Intramuscular Injection of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Severe Buerger's Disease.

Authors:  Jeong Chan Ra; Euicheol C Jeong; Sung Keun Kang; Seog Ju Lee; Kyoung Ho Choi
Journal:  Cell Med       Date:  2016-10-03

5.  Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds.

Authors:  Kara L Spiller; Sina Nassiri; Claire E Witherel; Rachel R Anfang; Johnathan Ng; Kenneth R Nakazawa; Tony Yu; Gordana Vunjak-Novakovic
Journal:  Biomaterials       Date:  2014-10-23       Impact factor: 12.479

6.  CD4 T-cells regulate angiogenesis and myogenesis.

Authors:  Brian J Kwee; Erica Budina; Alexander J Najibi; David J Mooney
Journal:  Biomaterials       Date:  2018-06-06       Impact factor: 12.479

Review 7.  Engineered circulatory scaffolds for building cardiac tissue.

Authors:  Shixing Huang; Yang Yang; Qi Yang; Qiang Zhao; Xiaofeng Ye
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

8.  Emulating native periosteum cell population and subsequent paracrine factor production to promote tissue engineered periosteum-mediated allograft healing.

Authors:  Michael D Hoffman; Danielle S W Benoit
Journal:  Biomaterials       Date:  2015-03-18       Impact factor: 12.479

9.  HYDROGEL-BASED NANOCOMPOSITES OF THERAPEUTIC PROTEINS FOR TISSUE REPAIR.

Authors:  Suwei Zhu; Tatiana Segura
Journal:  Curr Opin Chem Eng       Date:  2014-05-01       Impact factor: 5.163

10.  Sequential release of nanoparticle payloads from ultrasonically burstable capsules.

Authors:  Stephen Kennedy; Jennifer Hu; Cathal Kearney; Hadas Skaat; Luo Gu; Marco Gentili; Herman Vandenburgh; David Mooney
Journal:  Biomaterials       Date:  2015-10-22       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.